These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 26141492)

  • 1. CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease.
    Djelti F; Braudeau J; Hudry E; Dhenain M; Varin J; Bièche I; Marquer C; Chali F; Ayciriex S; Auzeil N; Alves S; Langui D; Potier MC; Laprevote O; Vidaud M; Duyckaerts C; Miles R; Aubourg P; Cartier N
    Brain; 2015 Aug; 138(Pt 8):2383-98. PubMed ID: 26141492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cholesterol and Alzheimer's disease].
    Kálmán J; Janka Z
    Orv Hetil; 2005 Sep; 146(37):1903-11. PubMed ID: 16255374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease.
    Boussicault L; Alves S; Lamazière A; Planques A; Heck N; Moumné L; Despres G; Bolte S; Hu A; Pagès C; Galvan L; Piguet F; Aubourg P; Cartier N; Caboche J; Betuing S
    Brain; 2016 Mar; 139(Pt 3):953-70. PubMed ID: 26912634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology.
    Burlot MA; Braudeau J; Michaelsen-Preusse K; Potier B; Ayciriex S; Varin J; Gautier B; Djelti F; Audrain M; Dauphinot L; Fernandez-Gomez FJ; Caillierez R; Laprévote O; Bièche I; Auzeil N; Potier MC; Dutar P; Korte M; Buée L; Blum D; Cartier N
    Hum Mol Genet; 2015 Nov; 24(21):5965-76. PubMed ID: 26358780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of cholesterol hydroxylases in Alzheimer's disease.
    Brown J; Theisler C; Silberman S; Magnuson D; Gottardi-Littell N; Lee JM; Yager D; Crowley J; Sambamurti K; Rahman MM; Reiss AB; Eckman CB; Wolozin B
    J Biol Chem; 2004 Aug; 279(33):34674-81. PubMed ID: 15148325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease.
    Hudry E; Van Dam D; Kulik W; De Deyn PP; Stet FS; Ahouansou O; Benraiss A; Delacourte A; Bougnères P; Aubourg P; Cartier N
    Mol Ther; 2010 Jan; 18(1):44-53. PubMed ID: 19654569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP46A1 protects against NMDA-mediated excitotoxicity in Huntington's disease: Analysis of lipid raft content.
    Boussicault L; Kacher R; Lamazière A; Vanhoutte P; Caboche J; Betuing S; Potier MC
    Biochimie; 2018 Oct; 153():70-79. PubMed ID: 30107216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo consequences of cholesterol-24S-hydroxylase (CYP46A1) inhibition by voriconazole on cholesterol homeostasis and function in the rat retina.
    Fourgeux C; Martine L; Acar N; Bron AM; Creuzot-Garcher CP; Bretillon L
    Biochem Biophys Res Commun; 2014 Apr; 446(3):775-81. PubMed ID: 24491555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP46A1 variants influence Alzheimer's disease risk and brain cholesterol metabolism.
    Kölsch H; Lütjohann D; Jessen F; Popp J; Hentschel F; Kelemen P; Schmitz S; Maier W; Heun R
    Eur Psychiatry; 2009 Apr; 24(3):183-90. PubMed ID: 19286353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer's disease mouse and reduces human P301L-tau content at the presymptomatic stage.
    Shibuya Y; Niu Z; Bryleva EY; Harris BT; Murphy SR; Kheirollah A; Bowen ZD; Chang CCY; Chang TY
    Neurobiol Aging; 2015 Jul; 36(7):2248-2259. PubMed ID: 25930235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antifungal drug voriconazole is an efficient inhibitor of brain cholesterol 24S-hydroxylase in vitro and in vivo.
    Shafaati M; Mast N; Beck O; Nayef R; Heo GY; Björkhem-Bergman L; Lütjohann D; Björkhem I; Pikuleva IA
    J Lipid Res; 2010 Feb; 51(2):318-23. PubMed ID: 19474457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease.
    Mast N; Saadane A; Valencia-Olvera A; Constans J; Maxfield E; Arakawa H; Li Y; Landreth G; Pikuleva IA
    Neuropharmacology; 2017 Sep; 123():465-476. PubMed ID: 28655608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A high-cholesterol diet enriched with polyphenols from Oriental plums (Prunus salicina) improves cognitive function and lowers brain cholesterol levels and neurodegenerative-related protein expression in mice.
    Kuo PH; Lin CI; Chen YH; Chiu WC; Lin SH
    Br J Nutr; 2015 May; 113(10):1550-7. PubMed ID: 25866056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of hypercholesterolemia in the outbreak of Alzheimer's disease and the treatment effect of Sibraea angustata extract].
    Sun WW; Xie BF; Liu H; Liu X
    Zhong Yao Cai; 2012 Apr; 35(4):596-602. PubMed ID: 23019908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol 24S-Hydroxylase Overexpression Inhibits the Liver X Receptor (LXR) Pathway by Activating Small Guanosine Triphosphate-Binding Proteins (sGTPases) in Neuronal Cells.
    Moutinho M; Nunes MJ; Gomes AQ; Gama MJ; Cedazo-Minguez A; Rodrigues CM; Björkhem I; Rodrigues E
    Mol Neurobiol; 2015; 51(3):1489-503. PubMed ID: 25084760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphism in the cholesterol 24S-hydroxylase gene (CYP46A1) associated with the APOEpsilon3 allele increases the risk of Alzheimer's disease and of mild cognitive impairment progressing to Alzheimer's disease.
    Fernández Del Pozo V; Alvarez Alvarez M; Fernández Martínez M; Galdós Alcelay L; Gómez Busto F; Peña JA; Alfonso-Sánchez MA; Zarranz Imirizaldu JJ; de Pancorbo MM
    Dement Geriatr Cogn Disord; 2006; 21(2):81-7. PubMed ID: 16340204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington's disease.
    Kacher R; Lamazière A; Heck N; Kappes V; Mounier C; Despres G; Dembitskaya Y; Perrin E; Christaller W; Sasidharan Nair S; Messent V; Cartier N; Vanhoutte P; Venance L; Saudou F; Néri C; Caboche J; Betuing S
    Brain; 2019 Aug; 142(8):2432-2450. PubMed ID: 31286142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuronal membrane cholesterol loss enhances amyloid peptide generation.
    Abad-Rodriguez J; Ledesma MD; Craessaerts K; Perga S; Medina M; Delacourte A; Dingwall C; De Strooper B; Dotti CG
    J Cell Biol; 2004 Dec; 167(5):953-60. PubMed ID: 15583033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromatin-modifying agents increase transcription of CYP46A1, a key player in brain cholesterol elimination.
    Milagre I; Nunes MJ; Moutinho M; Rivera I; Fuso A; Scarpa S; Gama MJ; Rodrigues E
    J Alzheimers Dis; 2010; 22(4):1209-21. PubMed ID: 20930312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).
    Uto Y
    Expert Opin Ther Pat; 2015 Mar; 25(3):373-7. PubMed ID: 25514969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.